Case todayNot read todayThesis-Break EngineThe case · mixed · Nov 9, 2026Own HYFT if its former ImmunoPrecise antibody/pharmaceutical platform can prove that specialized discovery demand supports high gross margins while management rightsizes spending fast enough to avoid dilution.4 conditions1 strengthening · 2 holding · 1 weakeningNext resultsNot scheduledNo date filed yet

HYFT at a glance

The past year

Chart

−46.0% $0.91, close Nov 17

From the highest close
−67.4%
Vs the 200-day average
−32.3%
Nov 14, 2025Daily close, MindWalk HoldingsNov 17, 2026

Short interest

History

1.1M shares

Since the last report
+4.3%
Days to cover
6.3 days
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 12 – Nov 18

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

HYFT price history

Latest price$0.87Today−$0.04 (-4.05%)
HYFT -34.59%S&P 500 -4.86%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

4 MATERIAL PROPOSITIONS
  • Biopharma customers must continue seeing MindWalk’s specialized antibody/pharmaceutical capabilities as worth outsourcing, so demand can expand without the company buying growth through price cuts or uneconomic work.HoldingMateriality: High

    IFRS annual revenue was CAD24.520m in FY2025, roughly unchanged from CAD24.518m in FY2024, so the customer base did not collapse despite losses. If specialized demand returns, the revenue base can absorb fixed scientific and corporate costs; if customers defect or insource, the business remains subscale.

    Watch: Large CROs or discovery vendors such as Charles River, WuXi Biologics, GenScript, Eurofins, or Thermo Fisher win outsourced antibody/discovery work on broader scale, lower price, or bundled offerings.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    IFRS annual revenue was CAD24.520m in FY2025, roughly unchanged from CAD24.518m in FY2024, so the customer base did not collapse.

    Open source ↗
  • MindWalk’s offering must remain technically differentiated enough to protect pricing and project mix, rather than drifting into commoditized low-margin discovery services.StrengtheningMateriality: High

    IFRS annual gross profit increased to CAD13.548m in FY2025 from CAD12.053m in FY2024 while revenue was essentially flat. Gross margin is the clearest evidence that customers pay for value, not just capacity; losing that would remove the main path to profitable scale.

    Watch: Price competition from larger CROs or antibody-discovery providers forces MindWalk to discount to keep utilization.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    IFRS annual gross profit increased to CAD13.548m in FY2025 from CAD12.053m in FY2024 while revenue was essentially flat.

    Open source ↗
  • Management must turn the fixed scientific, platform, and corporate cost base into operating leverage; otherwise even attractive gross margins will not create owner value.WeakeningMateriality: Medium

    IFRS annual operating cash flow was negative CAD6.410m in FY2025, far better than negative CAD19.833m in FY2023, suggesting cash burn can be managed. This is the difference between a scalable platform and a perpetual cash-burn story.

    Watch: Management continues funding broad R&D, AI, platform, or therapeutic ambitions without corresponding commercial partnerships.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    IFRS annual operating cash flow was negative CAD6.410m in FY2025, far better than negative CAD19.833m in FY2023, suggesting cash burn.

    Open source ↗
  • The balance sheet must provide enough runway for a commercial or cost-structure inflection, or the next funding step will capture value from shareholders through dilution or restrictive capital.HoldingMateriality: Medium

    Cash was CAD10.791m at FY2025 year-end, up from CAD3.545m at FY2024 year-end. For an unprofitable microcap, survival financing can dominate business progress and determine per-share outcomes.

    Watch: MindWalk cannot secure non-dilutive partnership, licensing, customer prepayment, grant, or asset-sale funding.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash was CAD10.791m at FY2025 year-end, up from CAD3.545m at FY2024 year-end.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Biopharma customers must continue seeing MindWalk’s specialized antibody/pharmaceutical capabilities as worth outsourcing, so demand can expand without the company buying growth through price cuts or uneconomic work. If specialized demand returns, the revenue base can absorb fixed scientific and corporate costs; if customers defect or insource, the business remains subscale.

MindWalk’s offering must remain technically differentiated enough to protect pricing and project mix, rather than drifting into commoditized low-margin discovery services. Gross margin is the clearest evidence that customers pay for value, not just capacity; losing that would remove the main path to profitable scale.

Management must turn the fixed scientific, platform, and corporate cost base into operating leverage; otherwise even attractive gross margins will not create owner value. This is the difference between a scalable platform and a perpetual cash-burn story.

The balance sheet must provide enough runway for a commercial or cost-structure inflection, or the next funding step will capture value from shareholders through dilution or restrictive capital. For an unprofitable microcap, survival financing can dominate business progress and determine per-share outcomes.

All standing thesis claims
Original report summary

its former ImmunoPrecise antibody/pharmaceutical platform can prove that specialized discovery demand supports high gross margins while management rightsizes spending fast enough to avoid dilution.

Evidence assessed Nov 9, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for MindWalk Holdings

Where the evidence on MindWalk Holdings disagrees: Mixed on the latest evidence (Nov 9, 2026). Of its 4 thesis points, 1 strengthening, 2 holding and 1 weakening.

Bull case: what the evidence supports

  • Biopharma customers must continue seeing MindWalk’s specialized antibody/pharmaceutical capabilities as worth outsourcing, so demand can expand without the company buying growth through price cuts or uneconomic work.

    sec.gov ↗

  • MindWalk’s offering must remain technically differentiated enough to protect pricing and project mix, rather than drifting into commoditized low-margin discovery services.

    sec.gov ↗

  • The balance sheet must provide enough runway for a commercial or cost-structure inflection, or the next funding step will capture value from shareholders through dilution or restrictive capital.

    sec.gov ↗

Bear case: what the evidence questions

  • Management must turn the fixed scientific, platform, and corporate cost base into operating leverage; otherwise even attractive gross margins will not create owner value.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · MindWalk Holdings

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

No break has crossed MindWalk Holdings’s thesis. Its break conditions are checked against every new filing as it lands.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Foreign issuer material report (6-K).

    MindWalk Holdings filed an SEC report on 2026-11-04: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.

  2. Mixed
    Foreign issuer material report (6-K).

    MindWalk Holdings filed an SEC report on 2026-10-28: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.

  3. Mixed
    Foreign issuer material report (6-K).

    MindWalk Holdings filed an SEC report on 2026-10-22: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Large CROs or discovery vendors such as Charles River, WuXi Biologics, GenScript, Eurofins, or Thermo Fisher win outsourced antibody/discovery work on broader scale, lower price, or bundled offerings.
  • Price competition from larger CROs or antibody-discovery providers forces MindWalk to discount to keep utilization.
  • Management continues funding broad R&D, AI, platform, or therapeutic ambitions without corresponding commercial partnerships.
  • MindWalk cannot secure non-dilutive partnership, licensing, customer prepayment, grant, or asset-sale funding.

HYFT news

Loading headlines…

Financial statements

HYFT income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

HYFT: quick answers

What is HYFT's short interest?
As of October 30, 2026, 1.1M HYFT shares were sold short, up 4.3% from the count before. At the stock's average daily volume that is 6.3 days to cover. FINRA publishes the count twice a month. HYFT short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.